Congenital Factor XIII is considered the rarest bleeding disorder but has the highest incidence of intracranial haemorrhage, so correct diagnosis is important. The barriers to market access are more prevalent in emerging economies, with lower use of replacement factors to…
Rare disease market research needs a multifaceted approach
Caroline Mathie discusses some of the challenges in researching rare diseases, what the broader market can learn from observing these approaches, and the role of online research in particular. Earlier this year, England’s chief medical officer called for the ‘genomic…
Gilead gains CAR-T approval, undercuts rival’s headline price
Gilead’s CAR-T cancer therapy has been approved in the US for an aggressive form of blood cancer, indicating the company’s $12 billion acquisition on Kite Pharma could pay off. Priced at $373,000 per patient, Gilead’s Yescarta (axicabtagene ciloleucel) has just…
Patient Engagement In Device Trials
Last week, the US Food and Drug Administration’s (FDA) Patient Engagement Advisory Committee (PEAC) met for the first time to look at ways to increase patient engagement in clinical trials for medical devices. Owen Faris, clinical trials director at the…
Apple patents Watch blood pressure monitoring tech
While its new line of smartphones dominates the headlines, Apple is continuing to push on with its healthcare ambitions, filing for a patent that would allow the Apple Watch to monitor blood pressure. The patent, entitled “Wrist Worn Accelerometer…
To market new drugs in India, global trials must include Indians
HIGHLIGHTS The move is expected to benefit clinical research organisations and hospitals operating in India The decision has been taken keeping in mind the safety of the Indian patients In a move to ensure efficacy of medicines sold in India,…
Another Acquisition: Ergomed to acquire CRO PSR Group for €5.7M
Ergomed, a specialized pharmaceutical services and drug development company, announced the proposed acquisition of PSR Group, an international niche CRO specialized in orphan drug development. Ergomed has agreed to acquire 100% of the issued share capital of PSR Group for…
The Rise of Real-World Evidence
Healthcare has been shifting to a value-based, personalized paradigm,” says Brett Davis, general manager, ConvergeHEALTH by Deloitte. “Reimbursement pressures and the unsustainability of the cost trajectory we’ve been on has been driving everyone to get to more of an outcomes-based…
The Intelligent Trial: AI Comes To Clinical Trials
Artificial intelligence is revolutionizing health care and advancing the clinical trial process faster than any Hollywood AI robot could predict. Besides cutting costs, improving trial quality, and reducing trial times by almost half, AI is finding biomarkers and gene signatures…
Rho, Bracket, Hearst, And More: News From September 2017
September was full of exciting news in the clinical trial and healthcare community, including partnerships, products, and promotions from Rho, Bracket, Hearst, and more. Hearst announced an equity investment in M2Gen one of the top comprehensive cancer centers in the United States.…
